- Date: 08-06-2026
- Extracted Insight:
- Stock Market Impact: GNI Group’s shares rose 11% in the week following the announcement, lifting its market capitalization to $986 million.
- Listed Companies and Sectors: GNI Group Co., Ltd. (TSE:2160) agreed to purchase 100% of Ayumi Pharmaceutical Holdings Co., Ltd. for approximately ¥44.8 billion, making Ayumi a wholly‑owned subsidiary and expanding GNI’s footprint in Japan’s pharma market, especially in pain management, rheumatology, and orthopedics. Ayumi’s flagship product Calonal holds over 80% of Japan’s acetaminophen market.
- Investment Flows: The transaction brings Blackstone, Toho and Hisamitsu onto GNI Group’s shareholder register, reflecting private‑equity and strategic investor participation.
- Fiscal or Monetary Policy: No related fiscal or monetary policy measures were mentioned.
- Relevance: Economic/Market-related
- Potential Market Impact: Positive – Immediate/Short-Term
GNI Group Acquires Ayumi Pharmaceutical for ¥44.8bn
M&A / Stake Purchase / Joint Venture
Price while announcement
Current price (CMP)